Figure 1.

Ligustilide mitigated the malignancy of HCC cells. (a) The chemical structure of ligustilide. (b) Cell viability was determined in normal hepatocytes after ligustilide treatment. (c) HCC cell line HepG2 was treated with the indicated doses of ligustilide. Then, CCK-8 assay was used to determine cell viability. (d) The protein expression of proliferation-related Ki67 was analyzed by Western blotting. (e and f) The effects of ligustilide on HCC cell apoptosis (e) and migration (f) were investigated. *P < 0.05 vs. control group. (A color version of this figure is available in the online journal.)